Clinical insomnia, estimated to affect 30 million people in the United States, is characterized by daytime dysfunction as a consequence of one or more of the following sleep problems: difficulty initiating and/or maintaining restorative sleep, early morning awakening, and intermittent wakefulness throughout the night. Primary treatment goals are to improve sleep quality and quantity and to improve insomnia-related daytime impairments, with minimal next-day side effects. While current therapies—largely composed of generic options, including benzodiazepines, non-benzodiazepine sedative-hypnotics, and antidepressants—are effective in their ability to improve sleep quality, they leave room for improvement on next-day functioning and residual psychomotor effects.
Using national patient-level claims data, the Treatment Algorithms in Insomnia report explores the use of key therapies and drug classes among newly diagnosed and recently treated insomnia patient populations. For the newly diagnosed patients, the report provides a quantitative analysis of percentage drug-treated and time to treatment, treatment patterns and share by line of therapy, as well as progression between lines, recent patient share trends, and use of concomitant treatment. For recently treated patients, the report quantifies a drug’s overall drug share, use in combination with other therapies, and source of business compared with its competitors, detailing which drugs precede others through an analysis of add-versus-switch patterns. Two additional claims database queries explore persistency and compliance by therapy.